[11C]sorafenib: radiosynthesis and preliminary PET study of brain uptake in P-gp/Bcrp knockout mice.

[1]  Ming-Rong Zhang,et al.  Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography. , 2011, Nuclear medicine and biology.

[2]  Ming-Rong Zhang,et al.  Evaluation of Limiting Brain Penetration Related to P-glycoprotein and Breast Cancer Resistance Protein Using [11C]GF120918 by PET in Mice , 2011, Molecular Imaging and Biology.

[3]  Ming-Rong Zhang,et al.  PET study on mice bearing human colon adenocarcinoma cells using [11C]GF120918, a dual radioligand for P-glycoprotein and breast cancer resistance protein , 2010, Nuclear medicine communications.

[4]  F. Dollé,et al.  [11C]Phosgene: A Versatile Reagent for Radioactive Carbonyl Insertion Into Medicinal Radiotracers for Positron Emission Tomography , 2010 .

[5]  T. Fukumura,et al.  Radiosynthesis of [2-(11)C-carbonyl]dantrolene using [(11)C]phosgene for PET. , 2010, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[6]  M. Radtke,et al.  In Vitro to In Vivo Comparison of the Substrate Characteristics of Sorafenib Tosylate toward P-Glycoprotein , 2010, Drug Metabolism and Disposition.

[7]  Jos H. Beijnen,et al.  Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation , 2010, Molecular Cancer Therapeutics.

[8]  T. Fukumura,et al.  Simple and effective method for producing [11C]phosgene using an environmental CCl4 gas detection tube. , 2010, Nuclear medicine and biology.

[9]  Kazunori Kawamura,et al.  [11C]Gefitinib ([11C]Iressa): Radiosynthesis, In Vitro Uptake, and In Vivo Imaging of Intact Murine Fibrosarcoma , 2010, Molecular Imaging and Biology.

[10]  I. Kanno,et al.  In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib. , 2009, Nuclear medicine and biology.

[11]  Jos H. Beijnen,et al.  Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment , 2009, Clinical Cancer Research.

[12]  J. Llovet,et al.  Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling , 2008, Molecular Cancer Therapeutics.

[13]  S. Grisanti,et al.  Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma , 2008, Journal of Neuro-Oncology.

[14]  O. Ranze,et al.  Renal Cell Cancer Presented with Leptomeningeal Carcinomatosis Effectively Treated with Sorafenib , 2007, Oncology Research and Treatment.

[15]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[16]  R. Pazdur,et al.  Sorafenib for the Treatment of Advanced Renal Cell Carcinoma , 2006, Clinical Cancer Research.

[17]  J. Beijnen,et al.  Blood–brain barrier and chemotherapeutic treatment of brain tumors , 2006, Expert review of neurotherapeutics.

[18]  A. Gee,et al.  Radiosynthesis of carbon‐11‐labelled GI181771, a new selective CCK‐A agonist , 2005 .

[19]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[20]  W. Elmquist,et al.  Distribution of STI-571 to the Brain Is Limited by P-Glycoprotein-Mediated Efflux , 2003, Journal of Pharmacology and Experimental Therapeutics.

[21]  G. Bollag,et al.  Discovery of a novel Raf kinase inhibitor. , 2001, Endocrine-related cancer.

[22]  N. Volkow,et al.  PET and drug research and development. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  P. Borst,et al.  Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.

[24]  I. Pastan,et al.  Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.

[25]  M. Diksic,et al.  Synthesis of "no-carrier-added" carbon-11 SarCNU: the sarcosinamide analog of the chemotherapeutic agent BCNU. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.